ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
Asthma Allergy News
 > Diabetes News
Women's Health News
Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
Ultrawide Field Retinal Imaging Improves Telehealth Evaluation
Image evaluation time was also reduced significantly for diabetic retinopathy with UWFI

WEDNESDAY, Aug. 21 (HealthDay News) -- Implementation of non-mydriatic ultrawide field retinal imaging (UWFI) in a telemedicine program significantly reduces the ungradable rate in evaluation of patients for diabetic retinopathy (DR) and diabetic macular edema (DME), compared to the use of non-mydriatic fundus photography (NMFP), according to a study published online Aug. 12 in Diabetes Care.

Paolo S. Silva, M.D., from Harvard Medical School in Boston, and colleagues retrospectively evaluated images (2,170 UWFI and 1,633 NMFP) for DR and DME at a centralized reading center with certified graders.

The researchers observed no significant differences between patients imaged using NMFP and UWFI with regards to age, diabetes duration, gender, ethnicity, or insulin use. For DR, the ungradable rate per patient was 2.9 percent for UWFI and 9.9 percent for NMFP; the corresponding numbers for DME were 3.8 and 8.8 percent. The median image evaluation time per patient was reduced from 12.8 to 9.2 minutes with UWFI. There was increased identification of patients with DR (38.4 versus 33.8 percent) and vision-threatening DR (14.5 versus 11.9 percent) with UWFI compared to NMFP.

"In a standardized DR ocular telehealth program, non-mydriatic UWFI reduced the ungradable rate by 71 percent (to less than 3 percent) and reduced image evaluation time by 28 percent," the authors write.

One of the two Optos P200MA instruments used in the study was provided by Optos.

Abstract
Full Text (subscription or payment may be required)



Copyright © 2013 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS